Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Short term Debt (2010 - 2024)

Standard Biotools (LAB) reported Short term Debt of $54.9 million for Q3 2024, up 998.26% year-over-year from $5.0 million in Q4 2023, and little changed on a QoQ basis from $54.8 million in Q2 2024.

Standard Biotools (LAB) has 6 years of Short term Debt data on file, last reported at $54.9 million in Q3 2024.

  • Quarterly Short term Debt rose 998.26% year-over-year to $54.9 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $54.9 million (up 998.26% YoY) and the FY2023 annual result came in at $54.5 million, changed N/A from the prior year.
  • Short term Debt held at $54.9 million in Q3 2024 per LAB's latest filing, from $54.8 million in the prior quarter.
  • Across five years, Short term Debt topped out at $54.9 million in Q3 2024 and bottomed at $3.3 million in Q1 2023.
  • The 3-year median for Short term Debt is $6.8 million (2021), against an average of $26.3 million.
  • Peak annual rise in Short term Debt reached 1095.35% in 2024, while the deepest fall reached 998.26% in 2024.
  • Tracing LAB's Short term Debt over 3 years: stood at $6.8 million in 2021, then surged by 697.46% to $54.5 million in 2023, then gained by 0.7% to $54.9 million in 2024.
  • Per Business Quant, the three latest LAB Short term Debt figures stand at $54.9 million (Q3 2024), $54.8 million (Q2 2024), and $54.5 million (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Standard Biotools 448.37 Mn -6.80 Mn 11.31 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2024 54.91 Mn
Jun 30, 2024 54.78 Mn
Dec 31, 2023 54.53 Mn
Sep 30, 2023 5.00 Mn
Jun 30, 2023 4.58 Mn
Mar 31, 2023 3.33 Mn
Dec 31, 2021 6.84 Mn
Sep 30, 2012 1.88 Mn
Jun 30, 2012 2.83 Mn
Mar 31, 2012 6.34 Mn
Dec 31, 2011 8.92 Mn
Sep 30, 2011 8.60 Mn
Mar 31, 2011 2.80 Mn
Dec 31, 2010 4.56 Mn